Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on...

Related Keywords

United States ,Russia ,Germany ,Ukraine ,Australia ,German ,Edna Kaplan ,Paula Schwartz ,Jessica Breu ,Daniel Vitt ,Immunic Inc ,Assembly Conference ,Exchange Commission ,Development Rd Expenses ,Rx Communications Group ,Nasdaq ,Association Of European Coeliac Societies ,Program In Relapsing Multiple Sclerosis Ongoing ,Trademark Office ,Significantly Strengthened Balance Sheet ,Three Tranche Private Placement ,Extending Cash Runway Into ,Third Quarter ,Neuroprotective Activity ,Vidofludimus Calcium ,Consistent Across ,Entire Progressive Multiple Sclerosis Population ,All Subtypes ,Relapsing Multiple Sclerosis Ongoing ,Expanded Vidofludimus Calcium Patent Portfolio ,Additional New Patents Granted ,Exclusivity Protection Expected Into ,Unless Extended Further ,Held Today ,Chief Executive Officer ,Avidity Partners ,Janus Henderson Investors ,Soleus Capital ,Adage Capital ,United States Patent ,European Coeliac Societies ,General Assembly Conference ,United European Gastroenterology Week ,German Federal Ministry ,Cash Equivalents ,Private Securities Litigation Reform Act ,Middle East ,Annual Report ,President Investor Relations ,Ended December ,Markets ,